Literature DB >> 24892705

Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.

Peter C Harris, Vicente E Torres.   

Abstract

Recent advances in defining the genetic mechanisms of disease causation and modification in autosomal dominant polycystic kidney disease (ADPKD) have helped to explain some extreme disease manifestations and other phenotypic variability. Studies of the ADPKD proteins, polycystin-1 and -2, and the development and characterization of animal models that better mimic the human disease, have also helped us to understand pathogenesis and facilitated treatment evaluation. In addition, an improved understanding of aberrant downstream pathways in ADPKD, such as proliferation/secretion-related signaling, energy metabolism, and activated macrophages, in which cAMP and calcium changes may play a role, is leading to the identification of therapeutic targets. Finally, results from recent and ongoing preclinical and clinical trials are greatly improving the prospects for available, effective ADPKD treatments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24892705      PMCID: PMC4089452          DOI: 10.1172/JCI72272

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  183 in total

Review 1.  Molecular pathways linking inflammation and cancer.

Authors:  A Mantovani
Journal:  Curr Mol Med       Date:  2010-06       Impact factor: 2.222

2.  PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.

Authors:  S O Marx; S Reiken; Y Hisamatsu; T Jayaraman; D Burkhoff; N Rosemblit; A R Marks
Journal:  Cell       Date:  2000-05-12       Impact factor: 41.582

Review 3.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

4.  Mechanisms underlying the resistance to diet-induced obesity in germ-free mice.

Authors:  Fredrik Bäckhed; Jill K Manchester; Clay F Semenkovich; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-08       Impact factor: 11.205

5.  PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.

Authors:  Daisuke Yoshihara; Hiroki Kurahashi; Miwa Morita; Masanori Kugita; Yoshiyuki Hiki; Harold M Aukema; Tamio Yamaguchi; James P Calvet; Darren P Wallace; Shizuko Nagao
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-08

6.  A ciliopathy complex at the transition zone protects the cilia as a privileged membrane domain.

Authors:  Ben Chih; Peter Liu; Yvonne Chinn; Cecile Chalouni; Laszlo G Komuves; Philip E Hass; Wendy Sandoval; Andrew S Peterson
Journal:  Nat Cell Biol       Date:  2011-12-18       Impact factor: 28.824

7.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

8.  Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology.

Authors:  Shuta Ishibe; Anil Karihaloo; Hong Ma; Junhui Zhang; Arnaud Marlier; Mitchihiro Mitobe; Akashi Togawa; Roland Schmitt; Jan Czyczk; Michael Kashgarian; David S Geller; Snorri S Thorgeirsson; Lloyd G Cantley
Journal:  Development       Date:  2009-01       Impact factor: 6.868

9.  The C. elegans homolog of the murine cystic kidney disease gene Tg737 functions in a ciliogenic pathway and is disrupted in osm-5 mutant worms.

Authors:  C J Haycraft; P Swoboda; P D Taulman; J H Thomas; B K Yoder
Journal:  Development       Date:  2001-05       Impact factor: 6.868

10.  Primary cilia are specialized calcium signalling organelles.

Authors:  Markus Delling; Paul G DeCaen; Julia F Doerner; Sebastien Febvay; David E Clapham
Journal:  Nature       Date:  2013-12-12       Impact factor: 49.962

View more
  137 in total

Review 1.  Emerging roles of extracellular vesicles in the nervous system.

Authors:  Lawrence Rajendran; Jitin Bali; Maureen M Barr; Felipe A Court; Eva-Maria Krämer-Albers; Frederic Picou; Graça Raposo; Kristan E van der Vos; Guillaume van Niel; Juan Wang; Xandra O Breakefield
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

Review 2.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

3.  The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.

Authors:  Hong Ye; Xiaofang Wang; Megan M Constans; Caroline R Sussman; Fouad T Chebib; María V Irazabal; William F Young; Peter C Harris; Lawrence S Kirschner; Vicente E Torres
Journal:  Am J Physiol Renal Physiol       Date:  2017-06-14

4.  Reciprocal regulation of cilia and autophagy via the MTOR and proteasome pathways.

Authors:  Shixuan Wang; Man J Livingston; Yunchao Su; Zheng Dong
Journal:  Autophagy       Date:  2015-04-03       Impact factor: 16.016

5.  Polycystin-1 regulates bone development through an interaction with the transcriptional coactivator TAZ.

Authors:  David Merrick; Kavita Mistry; Jingshing Wu; Nikolay Gresko; Julie E Baggs; John B Hogenesch; Zhaoxia Sun; Michael J Caplan
Journal:  Hum Mol Genet       Date:  2019-01-01       Impact factor: 6.150

6.  Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor γ agonists.

Authors:  Stephanie M Flaig; Vincent H Gattone; Bonnie L Blazer-Yost
Journal:  J Transl Int Med       Date:  2016-09-23

7.  Synergistic Genetic Interactions between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models.

Authors:  Rory J Olson; Katharina Hopp; Harrison Wells; Jessica M Smith; Jessica Furtado; Megan M Constans; Diana L Escobar; Aron M Geurts; Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2019-08-19       Impact factor: 10.121

Review 8.  Therapeutic Targets in Polycystic Liver Disease.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

9.  Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.

Authors:  Debbie Zittema; Irina B Versteeg; Ron T Gansevoort; Harry van Goor; Emile de Heer; Kimberley A M Veraar; Dorien J M Peters; Esther Meijer
Journal:  Am J Nephrol       Date:  2016-08-31       Impact factor: 3.754

Review 10.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.